Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat ITP

The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in patients with previously treated immune thrombocytopenia.
Medscape Medical News

source https://www.medscape.com/viewarticle/rilzabrutinib-shines-phase-3-trial-tough-treat-immune-2024a1000mlv?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost